title: Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
abstract: Persistence of HIV-1 in latently infected CD4(+) T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.
authors: Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
authors: Mary E
authors: ME
authors: Manson McManamy
authors: Shweta
authors: S
authors: Hakre
authors: Eric M
authors: EM
authors: Verdin
authors: David M
authors: DM
authors: Margolis
mesh_terms: D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D017735:Virus Latency / Q000187:drug effects*
chemical_list: D056572:Histone Deacetylase Inhibitors